Drugs / 99mTc-rhAnnexin V-128
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02182609 | Apr 2013 → Oct 2014 | — | Advanced Accelerator Applications | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02328027 | Dec 2014 → Oct 2017 | ankylosing spondylitis | Advanced Accelerator Applications | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-rhAnnexin V-128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02328027 ↗ |
| Modality | Diagnostic / imaging agent | “Nuclear Medicine Imaging” NCT02182609 ↗ |
| Route | Intravenous | “administered as an intravenous bolus” NCT02182609 ↗ |